About
Dr. David Lacey spent 17 years at Amgen, where he led the company's Discovery Research organization and its team of over 1,200 scientists working on drug discovery across haematology, oncology, inflammation, metabolic disorders, and neuroscience. He contributed to bone biology research underlying the development of Prolia (denosumab) and XGEVA, and previously served on the faculty at Washington University Medical Center in St. Louis. He holds a Bachelor's degree in Biology and an MD from the University of Colorado and is board certified in anatomical pathology.
Invests in
Biotech
Experience
- Inbiomotion SLNon Executive Directorcurrent2012 — presentGreater Barcelona Metropolitan Area
- David L Lacey LLCBiopharmaceutical Consultantcurrent2011 — present
- University of ColoradoAdvisercurrent2011 — present
- Cancer Support CommunityBoard Member2012 — 2015
- Cancer Support CommunityBoard Member2012 — 2015
- BayBio InstituteTrustee2011 — 2013
- AmgenSenior Vice President, Discovery Research2006 — 2011San Francisco Bay Area
Skills & more
Molecular Biology20Biotechnology99Clinical Development44Clinical Trials23Drug Discovery73Oncology38Infectious Diseases8Strategic Planning6Research5Lifesciences51CRO9R&D7
+12 more
CommercializationBiopharmaceuticalsClinical ResearchStart-upsPharmaceutical IndustryDrug DevelopmentCross-functional Team LeadershipImmunologyBiomarkersRegulatory AffairsMedical DevicesStrategyFrom David's professional profile.
Colleagues at Ysios Capital
Almudena Méndez
Associate at Ysios Capital
Antoni Ribas
Venture Partner at Ysios Capital
Arturo Urrios
Partner at Ysios Capital
Carlos Garcia-Echeverria
Venture Partner at Ysios Capital
Carlos Paya
Venture Partner at Ysios Capital
Catalina Cuchy
Executive Assistant at Ysios Capital
Cristina Garmendia
General Partner at Ysios Capital
Guillem Laporta
Partner at Ysios Capital
Frequently asked questions
- Who is David L. Lacey?
- Dr. David Lacey spent 17 years at Amgen, where he led the company's Discovery Research organization and its team of over 1,200 scientists working on drug discovery across haematology, oncology, inflammation, metabolic disorders, and neuroscience. He contributed to bone biology research underlying the development of Prolia (denosumab) and XGEVA, and previously served on the faculty at Washington University Medical Center in St. Louis. He holds a Bachelor's degree in Biology and an MD from the University of Colorado and is board certified in anatomical pathology.
- Where does David L. Lacey work?
- David L. Lacey is Venture Partner at Ysios Capital.
- What does David L. Lacey invest in?
- David L. Lacey invests in Biotech.
- Where did David L. Lacey go to school?
- David L. Lacey studied at University of Colorado Anschutz School of Medicine.
Same school
Also attended University of Colorado Anschutz School of Medicine1
Shared employers
Also worked at Inbiomotion SL4
Also worked at University of Colorado10
Kirsten SuddathInvestor at Next Frontier CapitalJamie FinneyFounder, Venture Partner at Greater Colorado Venture FundNoah PittardFounder, Special Advisor at Service Provider CapitalJonathan GoldsteinPartner at Narrow Gauge VenturesMark LupaGeneral Partner at Buff Gold VenturesZoe WelzPrincipal at Avesta Fund
+ 4 more
Also worked at Amgen65
Parker ConradCo-founder & CEO of RipplingSeth LieblichInvestment Team at 8VCSean BruichChief Technology Officer at Flare Capital PartnersSteph ScottVice President at Questa CapitalBeth SeidenbergFounding Managing Director at Westlake Village BioPartnersKelli McKeirnanDirector of Administration at Westlake Village BioPartners
+ 59 more